European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume 30, Issue 8, Pages 1648-1671
Publisher
Springer Nature
Online
2016-04-28
DOI
10.1038/leu.2016.104
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- Cardiovascular and pulmonary adverse events in patients treated withBCR-ABLinhibitors: Data from the FDA Adverse Event Reporting System
- (2015) Jorge Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia
- (2015) Delphine Rea ANNALS OF HEMATOLOGY
- Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina
- (2015) Jianxiang Wang et al. BLOOD
- Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
- (2015) J S L Kloth et al. BRITISH JOURNAL OF CANCER
- Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
- (2015) L Kalmanti et al. LEUKEMIA
- Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
- (2015) A Hochhaus et al. LEUKEMIA
- Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
- (2015) Luis-Felipe Casado et al. Cancer Medicine
- Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
- (2014) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
- (2014) Ulrike Proetel et al. ANNALS OF HEMATOLOGY
- Interaction of platelet-derived autotaxin with tumor integrin V 3 controls metastasis of breast cancer cells to bone
- (2014) R. Leblanc et al. BLOOD
- Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
- (2014) N. P. Shah et al. BLOOD
- Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
- (2014) P. Valent et al. BLOOD
- Bosutinibversusimatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
- (2014) Tim H. Brümmendorf et al. BRITISH JOURNAL OF HAEMATOLOGY
- Patient-reported outcomes in acute leukemia: a roadmap for future research
- (2014) Fabio Efficace et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome
- (2014) Tristan Mirault et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia
- (2014) D. Rea et al. HAEMATOLOGICA
- Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study
- (2014) Michele Baccarani et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study
- (2014) Mar Llamas-Velasco et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia
- (2014) D Rea et al. LEUKEMIA
- Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
- (2013) Paul La Rosée et al. ANNALS OF HEMATOLOGY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- How I treat leukemia during pregnancy
- (2013) D. Milojkovic et al. BLOOD
- Autocrine TNF- production supports CML stem and progenitor cell survival and enhances their proliferation
- (2013) P. Gallipoli et al. BLOOD
- Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling
- (2013) H. de Lavallade et al. BLOOD
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia
- (2013) Michael W. Deininger et al. BRITISH JOURNAL OF HAEMATOLOGY
- Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
- (2013) Daryl Sonnichsen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Dasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect?
- (2013) Semra Paydas CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
- (2013) Devron R. Shah et al. DRUG SAFETY
- Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study
- (2013) Luciano Levato et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia
- (2013) A. Nazha et al. HAEMATOLOGICA
- Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity
- (2013) Lars Harbaum et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report
- (2013) G. Kaiafa et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Management of Patients With Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations)
- (2013) Jeffrey L. Anderson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience
- (2013) V. Brazzelli et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Multiple eruptive dermatofibromas related to imatinib treatment
- (2013) M. Llamas-Velasco et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib
- (2013) K Mayer et al. LEUKEMIA
- Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
- (2013) T D Kim et al. LEUKEMIA
- Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
- (2013) F J Giles et al. LEUKEMIA
- Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
- (2013) Massimo Breccia et al. LEUKEMIA RESEARCH
- Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors
- (2013) Ellin Berman et al. LEUKEMIA RESEARCH
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Resolution Computed Tomography Findings for Patients With Drug-Induced Pulmonary Toxicity, With Special Reference to Hypersensitivity Pneumonitis-Like Patterns in Gemcitabine-Induced Cases
- (2013) M. Tamura et al. ONCOLOGIST
- The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
- (2012) Wing L. Ho et al. ACTA OPHTHALMOLOGICA
- Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure
- (2012) Takashi Onaka et al. AMERICAN JOURNAL OF HEMATOLOGY
- Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?
- (2012) Fabio Efficace et al. ANNALS OF HEMATOLOGY
- Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
- (2012) H. J. Khoury et al. BLOOD
- Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival
- (2012) S. M. Ranuncolo et al. BLOOD
- The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
- (2012) A. Giannoudis et al. BLOOD
- A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
- (2012) J. P. Radich et al. BLOOD
- Dasatinib inhibits proinflammatory functions of mature human neutrophils
- (2012) K. Futosi et al. BLOOD
- Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis
- (2012) Yi Ling Teo et al. CANCER TREATMENT REVIEWS
- Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
- (2012) David Montani et al. CIRCULATION
- Nilotinib-Associated Vascular Events
- (2012) Alfonso Quintás-Cardama et al. Clinical Lymphoma Myeloma & Leukemia
- Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization
- (2012) Aaron M. Drucker et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy
- (2012) P. Neelakantan et al. HAEMATOLOGICA
- Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
- (2012) F. Guilhot et al. HAEMATOLOGICA
- Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia
- (2012) Roberto Latagliata et al. HEMATOLOGICAL ONCOLOGY
- Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients
- (2012) Hideo Tanaka et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
- (2012) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
- (2012) F J Giles et al. LEUKEMIA
- Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
- (2012) S Mustjoki et al. LEUKEMIA
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
- (2012) R A Larson et al. LEUKEMIA
- Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia
- (2012) Juan Luis Steegmann et al. LEUKEMIA & LYMPHOMA
- Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications
- (2012) Gilhen H. Rodriguez et al. LEUKEMIA & LYMPHOMA
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Choosing the right TKI for chronic myeloid leukemia: When the truth lies in “long-term” safety and efficacy
- (2011) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia
- (2011) Su Jin Lee et al. AMERICAN JOURNAL OF HEMATOLOGY
- Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
- (2011) Karl J. Aichberger et al. AMERICAN JOURNAL OF HEMATOLOGY
- Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia
- (2011) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients
- (2011) M. S. Marcolino et al. ANNALS OF ONCOLOGY
- Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
- (2011) Massimo Breccia et al. BIODRUGS
- Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
- (2011) F. Efficace et al. BLOOD
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Expanding Nilotinib Access in Clinical Trials (ENACT)
- (2011) Franck E. Nicolini et al. CANCER
- A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects
- (2011) Richat Abbas et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
- (2011) Gianantonio Rosti et al. CANCER TREATMENT REVIEWS
- Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib
- (2011) IRIS AMITAY-LAISH et al. Dermatologic Therapy
- Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia
- (2011) D. Dumitrescu et al. EUROPEAN RESPIRATORY JOURNAL
- Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib
- (2011) M. Breccia et al. HAEMATOLOGICA
- Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy
- (2011) Dongho Kim et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
- (2011) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Peripheral neuropathy as an adverse effect of imatinib therapy
- (2011) Geothy Chakupurakal et al. JOURNAL OF CLINICAL PATHOLOGY
- Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
- (2011) M. Iyoda et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
- (2011) Carlo Gambacorti-Passerini et al. JNCI-Journal of the National Cancer Institute
- Severe Peripheral Arterial Disease During Nilotinib Therapy
- (2011) P. Le Coutre et al. JNCI-Journal of the National Cancer Institute
- Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
- (2011) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
- (2011) A Kreutzman et al. LEUKEMIA
- Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis
- (2011) Franck E. Nicolini et al. LEUKEMIA & LYMPHOMA
- Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study
- (2011) Fermin M. Sánchez-Guijo et al. LEUKEMIA RESEARCH
- LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
- (2011) Massimo Breccia et al. Mediterranean Journal of Hematology and Infectious Diseases
- CML: how low can you go?
- (2010) C. A. Schiffer BLOOD
- Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
- (2010) H. M. Kantarjian et al. BLOOD
- Activity and tolerability of nilotinib
- (2010) Maya Koren-Michowitz et al. CANCER
- Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors
- (2010) Faye M. Johnson et al. CANCER
- Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study
- (2010) Giuseppe Saglio et al. CANCER
- Practical management of tyrosine kinase inhibitor-associated side effects in GIST
- (2010) Heikki Joensuu et al. CANCER TREATMENT REVIEWS
- Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
- (2010) N. P. Shah et al. HAEMATOLOGICA
- The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients
- (2010) Milena S. Marcolino et al. HEMATOLOGICAL ONCOLOGY
- The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
- (2010) Julia Salih et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
- (2010) Yasunobu Nagata et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Nilotinib in a Patient With Postnecrotic Liver Cirrhosis Related to Imatinib
- (2010) Vito Spataro JOURNAL OF CLINICAL ONCOLOGY
- Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase
- (2010) M. Sonmez et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia
- (2010) Milena Soriano Marcolino et al. LEUKEMIA RESEARCH
- Reversible hair depigmentation in a patient treated with imatinib
- (2010) Stefania Mariani et al. LEUKEMIA RESEARCH
- A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib
- (2010) Zahra Raisi Estabragh et al. LEUKEMIA RESEARCH
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute Renal Failure under Dasatinib Therapy
- (2010) Sultan Ozkurt et al. RENAL FAILURE
- Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
- (2010) Theo D. Kim et al. THYROID
- Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice
- (2010) Nicole M Agostino et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Cardiotoxicity induced by tyrosine kinase inhibitors
- (2009) George S. Orphanos et al. ACTA ONCOLOGICA
- Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
- (2009) F. Castagnetti et al. BLOOD
- Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
- (2009) A. Quintas-Cardama et al. BLOOD
- Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
- (2009) G. Rosti et al. BLOOD
- The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo
- (2009) M.-P. Gratacap et al. BLOOD
- Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
- (2009) Alfonso Quintás-Cardama et al. CANCER
- Dasatinib treatment for Philadelphia chromosome-positive leukemias
- (2009) Hanna Jean Khoury et al. CANCER
- Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion
- (2009) Kimmo Porkka et al. CANCER
- Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
- (2009) C. Sillaber et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia
- (2009) J. M. A. Daniels et al. EUROPEAN RESPIRATORY JOURNAL
- Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
- (2009) F. Palandri et al. HAEMATOLOGICA
- Ocular Side Effects Associated with Imatinib Mesylate and Perifosine for Gastrointestinal Stromal Tumor
- (2009) S. Serdar Dogan et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine
- (2009) INTERNAL MEDICINE JOURNAL
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
- (2009) Jane F. Apperley et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
- (2009) S Mustjoki et al. LEUKEMIA
- Nilotinib post-liver transplantation for acute hepatic failure related to imatinib
- (2009) Guilherme F. Perini et al. LEUKEMIA RESEARCH
- Hypolipemiant besides antileukemic effect of imatinib mesylate
- (2009) Radu Gologan et al. LEUKEMIA RESEARCH
- Renal failure associated with tyrosine kinase inhibitors—Case report and review of the literature
- (2009) Anat Gafter-Gvili et al. LEUKEMIA RESEARCH
- Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors
- (2009) Onder Tonyali et al. MEDICAL ONCOLOGY
- Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss
- (2008) Helene François et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Bullous Sweet Syndrome in a Patient With t(9;22)(q34;q11)-Positive Chronic Myeloid Leukemia Treated With the Tyrosine Kinase Inhibitor Nilotinib
- (2008) Kjell Matthias Kaune et al. ARCHIVES OF DERMATOLOGY
- Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient
- (2008) D Mattei et al. BONE MARROW TRANSPLANTATION
- Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis
- (2008) Hugues de Lavallade et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
- (2008) M. Brave et al. CLINICAL CANCER RESEARCH
- Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib
- (2008) M. Hazarika et al. CLINICAL CANCER RESEARCH
- Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update
- (2008) R. Seggewiss et al. CYTOTHERAPY
- Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib
- (2008) A. Franceschino et al. HAEMATOLOGICA
- Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
- (2008) D. H. Kim et al. HAEMATOLOGICA
- Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy
- (2008) Shilen Lakhani et al. Hepatology International
- Optic disc edema as a possible complication of Imatinib mesylate (Gleevec)
- (2008) Soon-Il Kwon et al. JAPANESE JOURNAL OF OPHTHALMOLOGY
- Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
- (2008) Neil P. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure
- (2008) M. Sonmez et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia
- (2008) G Caocci et al. LEUKEMIA
- Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
- (2008) A Hochhaus et al. LEUKEMIA
- An evaluation of the cardiotoxicity of imatinib mesylate
- (2008) Antonio Luiz Ribeiro et al. LEUKEMIA RESEARCH
- Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib
- (2008) M. Breccia et al. LEUKEMIA RESEARCH
- Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia
- (2008) Sarah A. Holstein et al. LEUKEMIA RESEARCH
- Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia
- (2008) Walid Rasheed et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started